Heptares and Takeda Initiate Drug Discovery Collaboration Focused on GPCR Linked to CNS Disorders
News Apr 18, 2011
During the collaboration, Heptares will leverage its proprietary StaR® (stabilised receptor) technology to engineer the first-ever thermally stabilised forms of the GPCR as the basis for the drug discovery programme. Heptares will also apply advanced structural biology*1 and rational drug design approaches*2 – including Biophysical Mapping™, X-ray crystallography and fragment screening – to characterise the GPCR's structure and to generate early leads. Takeda will participate in lead generation and then assume responsibility for preclinical development and clinical development of new drugs candidates.
Under the terms of the agreement, Takeda receives worldwide commercial rights to new drugs emerging from the collaboration. Upon signing, Heptares received an upfront payment of £1.7 million and an investment in an equity stake of approximately £2.8 million purchased by Takeda Ventures Inc., a wholly-owned subsidiary of Takeda. Heptares is also eligible to receive future milestone payments of up to £60.5 million*3 plus royalties on product sales. Further terms of the agreement are not being disclosed.
"We are excited to be collaborating with Takeda to unlock a key GPCR target for treating CNS disorders, an area of significant unmet medical need where Takeda has established a leading scientific and commercial position," said Malcolm Weir, CEO of Heptares Therapeutics. "As we advance Heptares’ internal pipeline of GPCR-targeted medicines, we also plan to pursue attractive external opportunities, such as this partnership with Takeda, to extend our technology broadly across the GPCR universe."
"The Heptares StaR® technology is a powerful new capability for discovering GPCR-targeted drugs and we look forward to applying it to a specific GPCR target of interest to Takeda in the area of neuroscience," said Shigenori Ohkawa, Chief Scientific Officer at Takeda Pharmaceutical Company. "The Heptares platform applies broadly to the GPCR target family and delivers stabilised forms that most precisely capture the pharmacological conformations of GPCRs as they exist in their natural cellular environments."
The synthetic opioid, MPTP, induces the onset of a form of Parkinson's disease. In a new study, researchers found that an enzyme in the body can metabolize compounds formed in the brain from alkaloids present in certain foods and tobacco into MPTP-like chemicals, triggering a neurodegenerative condition in mice.READ MORE